^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
human anti CD19 CAR-T cells
i
Other names: human anti CD19 CAR-T cells, human antiCD19 Chimeric Antigen Receptor T cells, fully human anti CD19 CAR-T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Case Comprehensive Cancer Center
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
over1year
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=31, Active, not recruiting, Benjamin Tomlinson | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Apr 2023
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • fludarabine IV • human anti CD19 CAR-T cells
2years
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=31, Active, not recruiting, Benjamin Tomlinson | Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • fludarabine IV • human anti CD19 CAR-T cells
over2years
The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. (PubMed, Clin Lymphoma Myeloma Leuk)
Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
Zynlonta (loncastuximab tesirine-lpyl) • human anti CD19 CAR-T cells
over2years
Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain (ASH 2021)
Lymphodepletion included cyclophosphamide (60mg/kg x 1) and fludarabine (25mg/m2/d x 3)...Treatment for CRS / ICANS included tocilizumab (n = 12), siltuximab (n = 4), anakinra (n = 3) and corticosteroids (n = 10)... Second generation antiCD19 CAR-T cells with TNFRS19 transmembrane domain have potent clinical activity. On-site manufacture was successful in all pts. This strategy, in combination with fresh product infusion, can make CAR-T cell therapy rapidly available for pts with high-risk r/r B cell lymphoma.
Clinical • P1 data • CAR T-Cell Therapy
|
CD8 (cluster of differentiation 8) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CCL19 (C-C Motif Chemokine Ligand 19)
|
cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • Sylvant (siltuximab) • Kineret (anakinra) • human anti CD19 CAR-T cells
3years
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=31, Active, not recruiting, Benjamin Tomlinson | Recruiting --> Active, not recruiting | N=18 --> 31 | Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 positive
|
fludarabine IV • cyclophosphamide intravenous • human anti CD19 CAR-T cells
Share via
